TABLE 1.
Characteristic | No. (% or Range) |
---|---|
Demographics | |
Sex | |
Male | 3100 (61) |
Female | 1986 (39) |
Age | |
Median | 59 (19-90) |
<60 | 1743 (53.1) |
≥60 | 1537 (46.9) |
Race | |
White | 4369 (85.9) |
African American | 412 (8.1) |
Other/unknown | 305 (6.0) |
Comorbidity score | |
0 | 4029 (59.8) |
1 | 829 (16.3) |
2+ | 228 (4.5) |
Insurance | |
Not insured | 226 (4.4) |
Private | 2849 (56.0) |
Government | 1953 (38.4) |
Treatment facility type | |
Community cancer program | 295 (5.8) |
Academic/research program | 1917 (37.7) |
Comprehensive cancer program/other | 2874 (56.5) |
Treatment facility location | |
Metro counties | 4098 (82.3) |
Urban counties | 794 (15.9) |
Rural counties | 88 (1.8) |
Income, US dollars | |
<48,000 | 2012 (39.7) |
≥48,000 | 3059 (60.3) |
Distance to treatment facility, miles | |
≤10 | 2391 (47.0) |
>10 | 2679 (52.7) |
Location | |
East | 1944 (38.2) |
Central | 1913 (37.6) |
West | 870 (17.1) |
Year of diagnosis | |
2010–2011 | 1105 (21.7) |
2012–2013 | 1702 (33.5) |
2014–2015 | 2279 (44.8) |
Disease characteristics | |
Clinical T stage | |
T1/T2 | 317 (6.2) |
T3 | 4312 (84.8) |
T4 | 428 (8.4) |
Clinical T size | |
<2 cm | 724 (14.2) |
2–5 cm | 2517 (49.5) |
>5 cm | 1237 (24.3) |
Clinical N stage | |
N0 | 2026 (39.8) |
N1 | 2408 (47.3) |
N2 | 607 (11.9) |
Grade | |
Well differentiated | 403 (7.9) |
Moderately differentiated | 3533 (69.5) |
Poorly differentiated | 537 (10.6) |
Microsatellite instability | |
Negative (stable) | 4450 (87.5) |
Positive (instable) | 636 (12.5) |
Treatment characteristics | |
Radiation dose, Gy | |
Median (Gy) | 50.4 (40.4–70.2) |
<50.4 | 769 (15.1) |
≥50.4 and <54 | 3754 (73.8) |
≥54 | 563 (11.1) |
Time from XRT to surgery | |
≤2 mos | 2679 (52.7) |
2–4mos | 2407 (47.3) |
Preoperative chemotherapy | |
Single agent | 2850 (56.0) |
Double agent | 2088 (41.1) |
Unknown | 148 (2.9) |
Note: If sum of percentages is <100, then the remaining data are missing/unreported. Gy, gray.